The Europe Antimicrobial Susceptibility Testing Market would witness market growth of 5.5% CAGR during the forecast period (2022-2028).
The healthcare sector is developing interest in the antimicrobial susceptibility testing market due to increased demand for automated products, including AST panels, AST cards, and high-tech automated systems that provide more accuracy, faster processing, and enhanced workflow. This results in an increase in the use of automated systems in pharmaceutical & biotechnology companies, creating a tremendous growth opportunity for the market.
In addition, opportunities exist in unexplored, emerging markets with great potential due to enhanced healthcare infrastructure, growth in unmet healthcare demands, and increased antibiotic resistance among populations. The antimicrobial susceptibility testing market is ripe for investment by industry leaders due to the availability of manual and automated testing products that provide results in less time and with greater precision.
The increasing incidence of disease burden has prompted biopharmaceutical companies to create effective medications to combat the proliferation of infectious diseases. In 2015, the Federal Government expanded DART and revised its objectives. The German Antimicrobial Resistance Strategy (DART) 2020 is a nationwide, cross-sectoral strategy statement from 2015 to 2020. DART 2020 has the following objectives: recognizing resistance changes at an early stage; retaining and improving therapy options; strengthening the One Health approach; breaking infection chains early and preventing infections; raising awareness and enhancing skills; and supporting research & development. The regional market's growth is anticipated to be facilitated by government initiatives.
The Germany market dominated the Europe Antimicrobial Susceptibility Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $328.7 million by 2028. The UK market is anticipated to grow at a CAGR of 4.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 6.3% during (2022 - 2028).
Based on Application, the market is segmented into Clinical Diagnostics, Drug Discovery & Development and Epidemiology & Others. Based on Method, the market is segmented into Automated Susceptibility Testing Instruments, Disk Diffusion, Etest Method, Agar Diffusion, and Genotyping Method. Based on Type, the market is segmented into Antibacterial, Antifungal, Antiparasitic, and Others. Based on End User, the market is segmented into Hospitals & Diagnostic centers, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and Clinical Research Organizations. Based on Product, the market is segmented into Automated Laboratory Instruments, Manual Laboratory Instruments, Culture & Growth Media and Consumables. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Antimicrobial Susceptibility Testing Market will Hit $4.9 Billion by 2028, at a CAGR of 5.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, Bruker Corporation, Accelerate Diagnostics, Inc., HiMedia Laboratories Pvt. Ltd., and F. Hoffmann-La Roche Ltd.
By Application
By Method
By Type
By End User
By Product
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
